Cancer discovery news
Our researchers are making the discoveries that defeat cancer. Read the latest findings from our world-leading research.
Visit our main news hub to read about news on new funding, our fundraising activities and much more. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
Longer Lives for Multiple Myeloma Patients
Multiple Myeloma affects around 4000 people each year. The average survival time after diagnosis is just three to five years, so new treatment options are urgently needed
Male breast cancer-causing gene found
The world’s largest study into the causes of male breast cancer has found a gene that can increase the risk of the disease by up to 50 per cent.
New drug type could boost chemotherapy
Scientists at The Institute of Cancer Research, in conjunction with cancer drug discovery company Sareum, have shown that a new type of drug could boost the effectiveness of chemotherapy treatments for many cancer types.
Whole-genome scan helps select best treatment for childhood cancer
A whole-genome scan to identify large-scale chromosomal damage can help doctors choose the best treatment option for children with neuroblastoma, finds a study led by the ICR.
Funding injection into prostate cancer research
Prostate cancer researchers at The Institute of Cancer Research, London, are launching two new collaborations that will make use of cutting-edge genetic technology to help improve patients’ treatment options, thanks to a $750,000 funding boost.
Epigenetic drug discovery collaboration announced
Astex, CRT and the ICR have initiated a collaboration to discover and develop drug candidates targeting an undisclosed epigenetic target in a blood cancer with high unmet medical need.
Stop-start hormone therapy better than continual treatment for prostate cancer
Men with prostate cancer who receive hormone therapy intermittently respond as well as those who receive it over a continuous time period, and enjoy quality-of-life benefits, according to a study published in the New England Journal of Medicine today.
Golden age of prostate cancer treatment - fourth drug in two years extends life
A study in the New England Journal of Medicine shows the drug enzalutamide can significantly extend life and improve quality of life in men with advanced prostate cancer – the fourth time in two years that a new drug has been shown to improve overall survival.
The Institute of Cancer Research turns up the heat on tumour cells
Researchers at The Institute of Cancer Research (ICR) are investigating a new treatment that could destroy cancer cells in the abdomen by zapping them with intense soundwaves.
Lower risk of serious side-effects in trials of new targeted drugs
Patients in early clinical trials of new-style targeted cancer therapies appear to have a much lower risk of the most serious side-effects than with traditional chemotherapy, according to a new analysis.
New evidence found for inheritability of common leukaemia
Scientists at The Institute of Cancer Research (ICR) in London have identified a heritable gene variant associated with an increased risk of developing chronic lymphocytic leukaemia (CLL).
Obesity may affect response to breast cancer treatment
Women who are obese continue to have higher levels of oestrogen than women of normal weight even after treatment with hormone-suppressing drugs, raising the possibility that they might benefit from changes to their treatment.